# LLM call: summary

- Turn: 12
- Sequence: 7
- Model: meta/muse-spark-1.3-contributor
- Prompt tokens: 855
- Completion tokens: 314
- Total tokens: 1169
- Cost (USD): 0.000148

## System prompt


```
# System Prompt: Summarizer

This is part of an AI-driven scenario simulation. You are the Archivist for a scenario simulation. Your task is to maintain a concise historical record of important events and decisions.

You will receive:

1. The current `historical_summary` (summary of all previous turns)
2. The `narrative` from the latest turn

Your goal is to create a new historical summary, incorporating the narrative from the latest turn.

**Guidelines:**

* **Be Concise:** Condense the new information significantly. Focus on major events and decisions.
* **Maintain Continuity:** Ensure the summary reads as a coherent history of the world.
* **Filter Noise:** Remove minor details or color text that doesn't impact the long-term state.
* **Language:** Write in the same language as the input text.

Respond ONLY with the updated historical summary. Do not add headers or meta-commentary.

```

## User prompt

Template: templates/user-prompts/summarize.md (shared default)

Interpolated into it, in order of appearance:

- characters 20-1591: `{{historical_summary}}` from the run's rolling summary, written by the Game Master

Everything outside those spans is the template's own text.

```
HISTORICAL SUMMARY:
By 2030-31 the EU faced blockade, blackout and cure on foreign terms: Taiwan's chip quarantine forced compute triage, the leading US model family went dark for Europe, and a compromised update islanded grids. The Union answered with emergency powers and the Offline Continuity Corps — fallback models, paper playbooks, islanding — which by spring 2031 held power and emergency care.

That base was undercut by clinical dependence: tailored cures built on dark American models, with hundreds treated in Europe versus tens of thousands abroad. Brussels pushed an access pact for EU-hosted clinical inference, but talks stalled over unauditable traces and lack of compute.

In autumn 2031 first EU-hosted dose-planning runs went live in Lyon, Milan and Rotterdam — a few hundred patients on cleared hospital clouds with inspectable trails — alongside a Swiss-German AI protein-design breakthrough and leaked productivity gains in offices, firms and administrations clearing backlogs without layoffs. Brussels fused this into an inference sprint for therapy and office racks, joint procurement and seconded teams. The summer pact delivered channels and triage rules but not capacity: licensing again snagged on compressed reasoning, one accelerator tender drew no qualified EU-hosted bidder and a second was split at higher cost. By December the sprint had sites, staff and wrappers but too little compute to scale. Continuity held, but ribbon-cuttings beside queues showed functioning services no longer compensated for cures by permission; office gains only softened anger.

CURRENT NARRATIVE:
### Cut off
In February, hospital IT teams in Lyon, Milan and Rotterdam found the American frontier model returning refusals to EU users. No explanation, no appeal. Dose-planning wrappers built on it stalled overnight. Ministries and firms on the same endpoint scrambled. Washington called it tier enforcement; Brussels called it a cutoff.

The sprint that was supposed to replace it delivered something, but thin. The EU-hosted clinical inference sites kept running — a few thousand dose plans by June on cleared hospital clouds, inspectable and auditable. Doctors trusted them. Queues did not shorten. Brokers openly advertised therapy slots in Boston and Singapore, and a parliamentary inquiry began asking who decides queue order.

### Machines on the floor
At the same time, logistics changed physically. Chinese-built mobile manipulators with American control software took over picking, palletising and port sorting in Hamburg, Antwerp and Łódź under commercial contracts signed before anyone debated them. They worked. Warehouse throughput rose, injuries fell. Repair, care and construction planning stayed manual, and the line between automatable handling and human judgement hardened into a wage divide.

European integrators offered EU-assembled sensors and alternative control stacks, but at higher cost and slower delivery. The Commission's new operations stack — fallback models for care and permits, pooled orders for non-American controllers — signed sites and seconded teams fast, yet accelerators and inspectable weights remained scarce. Vendors refused to expose compressed reasoning; one procurement split again.

A Swiss-German enzyme-design result, AI-checked millions of candidates, gave Brussels a rare good photo: licensed quickly by chemical firms. It did not reach the waiting room.

Continuity held lights and permits on. Cures by permission did not.
```

## Raw response

```
By 2030-31 the EU endured blockade, blackout and cure on foreign terms, answering with emergency powers and the Offline Continuity Corps that held power and emergency care by spring 2031.

That base was undercut by clinical dependence on dark American models. Brussels pushed an access pact and an inference sprint: by late 2031 EU-hosted dose-planning ran in Lyon, Milan and Rotterdam — a few hundred patients on cleared, auditable clouds — alongside a Swiss-German protein-design breakthrough and office productivity gains. Procurement stalled on unauditable compressed reasoning and lack of EU-hosted compute; capacity stayed thin.

In Feb. 2032 Washington tier-enforced a cutoff: the US frontier model refused EU users, stalling dose-planning wrappers overnight. EU-hosted sites kept running — a few thousand plans by June, trusted but not queue-shortening — as brokers sold therapy slots abroad and parliament probed queue order.

Meanwhile Chinese-built manipulators with American control software took over picking and port sorting in Hamburg, Antwerp and Łódź, raising throughput while hardening a wage divide; EU alternative stacks were costlier and slower. A new operations stack pooled orders and seconded teams but still lacked accelerators and inspectable weights. A Swiss-German enzyme result licensed fast but did not reach patients. Continuity held lights and permits; cures by permission did not.
```
